VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

SABCS 2020 | MARIO-3: eganelisib in TNBC

Erika Hamilton, MD, Sarah Cannon Research Institute, Nashville, TN, discusses the results of the MARIO-3 (NCT03961698), a Phase II study in triple-negative breast cancer (TNBC) evaluating eganelisib, a first-in-class, oral PI3K-gamma inhibitor in combination with nab-paclitaxel and atezolizumab. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).


Dr. Hamilton reports consulting fees paid to institution only (no personal fees) from: Pfizer, Genentech/Roche, Lilly, Puma Biotechnology, Daiichi Sankyo, Mersana Therapeutics, Boehringer Ingelheim, AstraZeneca, Novartis, Silverback Therapeutics, Black Diamond and NanoString

Dr. Hamilton reports and research/clinical trial support paid to institution only (no personal fees) from: Seattle Genetics, Puma, AstraZeneca, Hutchinson MediPharma, OncoMed, MedImmune, StemCentrx, Genentech/Roche, Curis, Verastem, Zymeworks, Syndax, Lycera, Rgenix, Novartis, Mersana, Millenium, TapImmune, Lilly, BerGenBio, Medivation, Pfizer, Tesaro, Boehringer Ingelheim, Eisai, H3 Biomedicine, Radius Health, Acerta, Takeda, Macrogenics, Abbvie, Immunomedics, FujiFilm, Effector, Merus, Nucana, Regeneron, Leap Therapeutics, Taiho Pharmaceutical, EMD Serono, Daiichi Sankyo, ArQule, Syros, Clovis, Cytomx, InventisBio, Deciphera, Unum Therapeutics, Sermonix Pharmaceuticals, Sutro, Aravive, Zenith Epigenetics, Arvinas, Torque, Harpoon, Fochon, Black Diamond, Orinove, Molecular Templates, Silverback Therapeutics, Compugen, G1Therapeutics, Karyopharm Therapeutics and Torque Therapeutics.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter